Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)

CAPS Rating: 3 out of 5

A biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer.

Results 1 - 19 of 19

Recs

0
Member Avatar Eric509 (< 20) Submitted: 8/11/2015 2:14:52 PM : Outperform Start Price: $4.17 THLD Score: +5.87

addressing tumor hypoxia seems to be the forward thinking approach

Recs

0
Member Avatar drugtrader (92.64) Submitted: 8/7/2015 11:31:12 AM : Underperform Start Price: $3.80 THLD Score: -17.46

Good treatment perhaps but I am wary of trial design and believe FDA will require more data. It's definitely worth a small bet and I hope they hit a home run out of the park right off the bat

Recs

0
Member Avatar walkmar (< 20) Submitted: 7/6/2015 11:13:20 AM : Outperform Start Price: $4.03 THLD Score: +8.84

Good earning growth. Solid and novel science behind product.

Recs

0
Member Avatar TerryFool (74.54) Submitted: 3/25/2014 5:50:51 AM : Outperform Start Price: $3.98 THLD Score: -2.96

BUY@ 4.3 TP 12

Recs

0
Member Avatar TerryHoodSr (78.78) Submitted: 9/4/2013 12:11:24 PM : Outperform Start Price: $5.26 THLD Score: -30.48

3yr REV 9%, spec

Recs

0
Member Avatar chris293 (72.55) Submitted: 7/31/2013 6:42:22 PM : Outperform Start Price: $5.48 THLD Score: -39.48

good earning growth bodes well for this stock.

Recs

0
Member Avatar scrubs62074 (47.47) Submitted: 2/20/2013 10:59:26 AM : Outperform Start Price: $4.84 THLD Score: -42.48

Bullish MACD crossover on 02/20/13

Recs

0
Member Avatar FWWright (21.63) Submitted: 10/25/2012 10:49:51 AM : Outperform Start Price: $4.55 THLD Score: -47.39

Pancreatic cancer is so bad that any drug that helps extend lives is valuable

Recs

0
Member Avatar EnigmaDude (76.12) Submitted: 10/17/2012 1:38:20 PM : Outperform Start Price: $5.17 THLD Score: -54.05

Threshold Pharmaceuticals Inc. (THLD) said the U.S. Food and Drug Administration reached agreement with a Threshold partner covering a special protocol assessment for a Phase 3 trial of TH-302, allowing the companies to push forward the study of the pancreatic cancer drug.

Recs

0
Member Avatar colbyt34 (< 20) Submitted: 7/6/2012 2:04:38 AM : Outperform Start Price: $7.91 THLD Score: -92.56

I believe once the data comes out for TH-302 and they get their milestone payments from Merck, its a done deal.

Recs

0
Member Avatar jdill23 (< 20) Submitted: 4/3/2012 3:19:17 PM : Underperform Start Price: $7.35 THLD Score: +82.95

They look to be way overvalued for what they have in cash, ect.

Recs

0
Member Avatar lindahappyhour (< 20) Submitted: 2/21/2012 5:42:03 PM : Outperform Start Price: $4.98 THLD Score: -59.19

biotech

Recs

0
Member Avatar STAINEDGLASSER (41.74) Submitted: 2/6/2012 1:26:49 PM : Outperform Start Price: $3.63 THLD Score: -31.16

They have numerous cancer drugs in the works that appear to be doing well in clinical trials. They recently inked a deal with Merck in Germany to commercialize one of their drugs, which is also an indication that they are doing well.

Recs

1
Member Avatar topsecret10 (< 20) Submitted: 4/1/2011 11:56:58 AM : Outperform Start Price: $1.60 THLD Score: +115.25

Latest direct offering netted company 30 million dollars. Insiders and Institutions have purchased over 5 million shares since early March. Stock Is now about 40 cents under their average buying prices. I love these little biotechs,and I like the drug discovery platform that this company Is using. Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

Recs

0
Member Avatar SorrySam (75.76) Submitted: 3/19/2011 12:25:26 AM : Outperform Start Price: $1.69 THLD Score: +96.27

insider buying

Recs

0
Member Avatar polvo23 (< 20) Submitted: 2/11/2007 7:51:58 PM : Outperform Start Price: $3.31 THLD Score: -18.55

phase 3...did all the research

Recs

0
Member Avatar epocrates (< 20) Submitted: 2/2/2007 10:47:48 AM : Underperform Start Price: $3.48 THLD Score: +23.90

Pancreatic cancer is hard to show survival. Refractory pancreatic cancer is impossible to survival.

Recs

2
Member Avatar Rhondalo (32.04) Submitted: 12/29/2006 11:45:56 AM : Outperform Start Price: $3.72 THLD Score: -34.55

Trials look positive for pancreatic cancer and they may resume clinical research for prostate cancer.

Recs

2
Member Avatar pwlkrphllp (50.13) Submitted: 12/29/2006 2:36:46 AM : Outperform Start Price: $4.11 THLD Score: -45.32

cancer

Results 1 - 19 of 19

Featured Broker Partners


Advertisement